Article: Sepracor Announces Publication of LUNESTA(TM) Insomnia-Depression Study in Biological Psychiatry.

Article: Lunesta Data Presented at 2005 Associated Professional ...
Business Wire;  June 21, 2005 ;     700+ words ... ... four oral presentations of LUNESTA(TM) brand eszopiclone ... patients in the placebo-fluoxetine group. The eszopiclone-fluoxetine ... group versus the placebo-fluoxetine group at each assessment (Weeks ... assessment, versus the placebo-fluoxetine group. Based on the ISI total ...

Article: LUNESTA(TM) Brand Eszopiclone, Formerly ESTORRA, Approved ...
PR Newswire;  December 16, 2004 ;     700+ words ... ... approved the New Drug Application (NDA) for LUNESTA(TM) brand eszopiclone, formerly referred ... for the FDA's decision to not limit LUNESTA's indication to short-term use. Sepracor ... study with no evidence of tolerance." LUNESTA is indicated for the treatment of patients ...

Article: LUNESTA(TM) Now Widely Available by Prescription to Treat ...
PR Newswire;  April 7, 2005 ;     700+ words ... ... Sepracor Inc. today announced that LUNESTA(TM) (eszopiclone 1 mg, 2 mg and 3 ... prescription in most pharmacies nationwide. LUNESTA is the first and only sleep aid (prescription ... for long-term treatment of insomnia. LUNESTA is the first treatment in its class that ...

Article: LUNESTA(TM) Perimenopause-Menopause Study Data to Be ...
Business Wire;  September 30, 2005 ;     700+ words ... ... study evaluating safety and efficacy of LUNESTA(TM) brand eszopiclone for treatment ... placebo-controlled study, nightly use of LUNESTA 3 mg resulted in statistically significant ... treatment period. Patients treated with LUNESTA also demonstrated significant improvements ...

Article: LUNESTA(TM) Data Presented at American College of ...
Business Wire;  November 15, 2005 ;     700+ words ... ... evaluating the safety and efficacy of LUNESTA(TM) brand eszopiclone for the treatment ... Diego. In this study, nightly use of LUNESTA 3 mg resulted in statistically significant ... Compared to placebo, patients administered LUNESTA also reported improvements in sleep quality ...

Article: Lunesta Data to Be Presented at American Psychiatric ...
Business Wire;  May 19, 2005 ;     700+ words ... ... that Phase III/IV clinical data for LUNESTA(TM) brand eszopiclone for the treatment ... Primary Insomnia Sepracor will also have a LUNESTA Booth (booth #2742) at APA from May ... began full-scale commercial launch of LUNESTA. LUNESTA, which is indicated for the ...

Article: Results of Sepracor's LUNESTA(R) Next-Day Driving Study in ...
Business Wire;  December 6, 2006 ;     700+ words ... ... presentation of results from a study of LUNESTA([R]) brand eszopiclone that measured ... with primary insomnia administered either LUNESTA 3 mg or placebo the evening before. Next ... following nighttime administration of LUNESTA 3 mg, compared with placebo. Consistent ...